Zalevsky Jonathan 4
4 · NEKTAR THERAPEUTICS · Filed May 21, 2026
Research Summary
AI-generated summary of this filing
Nektar (NKTR) Chief R&D Officer Jonathan Zalevsky Sells Shares
What Happened
Jonathan Zalevsky, Chief Research & Development Officer at Nektar Therapeutics (NKTR), sold 199 shares on 2026-05-19 at a weighted average price of $65.51, for total proceeds of approximately $13,036. The filing reports the transaction as a sale (code S) executed via open market or private sale.
Key Details
- Transaction date: 2026-05-19 (Form 4 filed 2026-05-21 — appears timely).
- Price: weighted average $65.51; individual trades ranged from $64.88 to $68.43 (per filing footnote).
- Shares sold: 199; proceeds ≈ $13,036.
- Reason: Footnote indicates the sale was to cover required tax withholding on vested RSUs and “does not represent a discretionary trade.” (Footnote F1)
- Additional note: The filing states the reporting person can provide full trade-by-trade details on request (Footnote F2).
- Shares owned after transaction: not specified in the provided summary — see the Form 4 for post-transaction holdings.
Context
This was a tax-withholding sale related to RSU vesting, which is routine for insiders and typically not interpreted as a signal about the executive’s view of the company. Purchases are generally more indicative of insider confidence; sales to cover taxes are common and administrative in nature.
Insider Transaction Report
Form 4
Zalevsky Jonathan
Chief R&D Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-05-19$65.51/sh−199$13,036→ 20,975 total
Footnotes (2)
- [F1]Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Signature
Elizabeth Zhang, Attorney-in-Fact|2026-05-21